Randomized phase II trial of custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c

Clinical Cancer Research

Volumn 17, Issue 17, 2011, Pages 5765-5773

  Saad, Fred ^a   Hotte, Sebastien ^c   North, Scott ^d   Eigl, Bernie ^e   Chi, Kim ^f   Czaykowski, Piotr ^h   Wood, Lori ⁱ   Pollak, Michael ^b   Berry, Scott ^j   Lattouf, Jean Baptiste ^a   Mukherjee, Som D ^c   Gleave, Martin ^g   Winquist, Eric ^k  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c JURAVINSKI CANCER CENTRE   (Canada)

^d CROSS CANCER INSTITUTE   (Canada)

^e TOM BAKER CANCER CENTRE   (Canada)

^f BRITISH COLUMBIA CANCER AGENCY   (Canada)

^g VANCOUVER PROSTATE CENTRE   (Canada)

^h CANCERCARE MANITOBA   (Canada)

ⁱ QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^j DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^k LONDON HEALTH SCIENCES CENTRE   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CLUSTERIN; CUSTIRSEN; DOCETAXEL; MITOXANTRONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BONE PAIN; BRONCHIOLITIS; CANCER PAIN; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CHILL; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEVER; HUMAN; HYPONATREMIA; INJECTION SITE INFECTION; INSOMNIA; LEUKOPENIA; LOADING DRUG DOSE; LYMPHOCYTOPENIA; MALE; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PAIN ASSESSMENT; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SEPTICEMIA; SIDE EFFECT; SYNCOPE; THORAX PAIN; URINARY TRACT INFECTION; VOMITING; WEAKNESS;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLUSTERIN; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MIDDLE AGED; MITOXANTRONE; NEOPLASM METASTASIS; ORCHIECTOMY; PREDNISONE; PROSTATIC NEOPLASMS; TAXOIDS; THIONUCLEOTIDES; TREATMENT OUTCOME;

EID: 80052468423     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0859     Document Type: Article

References (37)

1. Tannock I.F., De Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-1512 (Pubitemid 39315317)
2. Petrylak D.P., Tangen C.M., Hussain M.H., Lara P.N. Jr., Jones J.A., Taplin M.E., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-1520 (Pubitemid 39315318)
3. Berthold D.R., Pond G.R., De Wit R., Eisenberger M., Tannock I.F. Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann Oncol 2008;19:1749-1753
4. Michels J., Montemurro T., Murray N., Kollmannsberger C., Nguyen Chi K. First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: Does sequence matter? Cancer 2006;106:1041-1046
5. Oh W.K., Manola J., Babcic V., Harnam N., Kantoff P.W. Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes. Urology 2006;67:1235-1240 (Pubitemid 43818095)
6. Rosenberg J.E., Ryan C.J., Weinberg V.K., Smith D.C., Hussain M., Beer T.M., et al. Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: A study of the department of defense prostate cancer clinical trials consortium. J Clin Oncol 2009;27:2772-2778
7. Zellweger T., Kiyama S., Chi K., Miyake H., Adomat H., Skov K., et al. Overexpression of the cytoprotective protein clusterin decreases radiosensitivity in the human LNCaP prostate tumour model. BJU Int 2003;92:463-469 (Pubitemid 37100531)
8. Miyake H., Fujisawa M. Promise of antisense oligodeoxynucleotide-based therapy for bladder cancer. Expert Rev Anticancer Ther 2008;8:1851-1854
9. Park D.C., Yeo S.G., Wilson M.R., Yerbury J.J., Kwong J., Welch W.R., et al. Clusterin interacts with Paclitaxel and confer Paclitaxel resistance in ovarian cancer. Neoplasia 2008;10:964-972
10. So A., Sinnemann S., Huntsman D., Fazli L., Gleave M. Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo. Mol Cancer Ther 2005;4:1837-1849 (Pubitemid 43056967)
11. July L.V., Beraldi E., So A., Fazli L., Evans K., English J.C., et al. Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo. Mol Cancer Ther 2004;3:223-232 (Pubitemid 39193697)
12. Miyake H., Hara I., Kamidono S., Gleave M.E., Eto H. Resistance to cytotoxic chemotherapy-induced apoptosis in human prostate cancer cells is associated with intracellular clusterin expression. Oncol Rep 2003;10:469-473
13. Zoubeidi A., Chi K., Gleave M. Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer. Clin Cancer Res 2010;16:1088-1093
14. Poon S., Easterbrook-Smith S.B., Rybchyn M.S., Carver J.A., Wilson M.R. Clusterin is an ATP-independent chaperone with very broad substrate specificity that stabilizes stressed proteins in a folding-competent state. Biochemistry 2000;39:15953-15960 (Pubitemid 32038257)
15. Wyatt A.R., Yerbury J.J., Wilson M.R. Structural characterization of clusterin-chaperone client protein complexes. J Biol Chem 2009;284:21920-21927
16. Zhang H., Kim J.K., Edwards C.A., Xu Z., Taichman R., Wang C.Y. Clusterin inhibits apoptosis by interacting with activated Bax. Nat Cell Biol 2005;7:909-915 (Pubitemid 41486292)
17. Zoubeidi A., Ettinger S., Beraldi E., Hadaschik B., Zardan A., Klomp L.W., et al. Clusterin facilitates COMMD1 and I-kappaB degradation to enhance NF-kappaB activity in prostate cancer cells. Mol Cancer Res 2010;8:119-130
18. Santilli G., Aronow B.J., Sala A. Essential requirement of apolipoprotein J (clusterin) signaling for IkappaB expression and regulation of NF-kappaB activity. J Biol Chem 2003;278:38214-38219 (Pubitemid 37221710)
19. Zellweger T., Miyake H., Cooper S., Chi K., Conklin B.S., Monia B.P., et al. Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2′-O-(2-methoxy)ethyl chemistry. J Pharmacol Exp Ther 2001;298:934-940 (Pubitemid 32761906)
20. Gleave M.E., Monia B.P. Antisense therapy for cancer. Nat Rev Cancer 2005;5:468-479 (Pubitemid 40791489)
21. Miyake H., Nelson C., Rennie P.S., Gleave M.E. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models. Cancer Res 2000;60:2547-2554 (Pubitemid 30262451)
22. Miyake H., Chi K.N., Gleave M.E. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. Clin Cancer Res 2000;6:1655-1663 (Pubitemid 30305057)
23. Miyake H., Nelson C., Rennie P.S., Gleave M.E. Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res 2000;60:170-176 (Pubitemid 30058748)
24. Miyake H., Hara I., Kamidono S., Gleave M.E. Synergistic chemsensitization and inhibition of tumor growth and metastasis by the antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model. Clin Cancer Res 2001;7:4245-4252 (Pubitemid 34044651)
25. Sowery R.D., Hadaschik B.A., So A.I., Zoubeidi A., Fazli L., Hurtado-Coll A., et al. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy. BJU Int 2008;102:389-397 (Pubitemid 352019195)
26. Chi K.N., Eisenhauer E., Fazli L., Jones E.C., Goldenberg S.L., Powers J., et al. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 2005;97:1287-1296 (Pubitemid 41535369)
27. Cleeland C.S. Measurement of pain by subjective report. New York: Raven Press; 1989.
28. Jadad A.R., Browman G.P. The WHO analgesic ladder for cancer pain management: Stepping up the quality of its evaluation. JAMA 1995;274:1870-1873 (Pubitemid 26001265)
29. Anderson J.R., Cain K.C., Gelber R.D. Analysis of survival by tumor response. J Clin Oncol 1983;1:710-719 (Pubitemid 14202071)
30. Tannock I.F., Osoba D., Stockler M.R., Ernst D.S., Neville A.J., Moore M.J., et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 1996;14:1756-1764 (Pubitemid 26185452)
31. Berthold D.R., Pond G., De Wit R., Eisenberger M.A., Tannock I.F. Treatment of hormomone-refractory prostate cancer with docetaxel or mitoxantrone: Relationships between prostate-specific antigent pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res 2008;14:2763-2767
32. Ansari J., Hussain S.A., Zarkar A., Tanguay J.S., Bliss J., Glaholm J. Docetaxel chemotherapy for metastatic hormone refractory prostate cancer as first-line palliative chemotherapy and subsequent re-treatment: Birmingham experience. Oncol Rep 2008;20:891-896
33. Jankovic B., Beardsley E., Chi K. Rechallenge with docetaxel as second-line chemotherapy in patients with metastatic hormone refractory prostate cancer (HRPC) after previous docetaxel: A population based analysis. [Abst. 196] 2008 ASCO Genitourinary Symposium; Chicago, Illinois; 2008.
34. Buonerba C., Palmieri G., Di Lorenzo G. Docetaxel rechallenge in castration-resistant prostate cancer: Scientific legitimacy of common clinical practice. Eur Urol 2010;58:636-637
35. De Bono J.S., Oudard S., Ozguroglu M., Hansen S., Machiels J.H., Kocak I., et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 2010;376:1147-1154
36. Chi K., Hotte S., Yu E., Tu D., Eigl B., Tannock I., et al. A randomized phase 2 study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration resistant prostate cancer. J Clin Oncol 2010;28:4247-4254
37. Zoubeidi A., Ettinger S., Beraldi E., Hadaschik B., Zardan A., Klomp L.W., et al. Clusterin facilitates COMMD1 and I-kappaB degradation to enhance NF-kappaB activity in prostate cancer cells. Mol Cancer Res 2010;8:119-130